SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentation at the 33rd Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PST, Wednesday, Jan. 14, 2015. The presentation will feature a business overview and update by Hans Bishop, president and chief executive officer of Juno.
The webcast will be accessible on the Investors page of Juno’s website at www.JunoTherapeutics.com. A replay of the presentation will be available at the same location for 30 days following the conference.
Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. Juno’s long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world’s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute, and The National Cancer Institute.
Forward Looking Statements
This press release contains forward-looking statements, including statements regarding Juno’s participation in the 33rd Annual J.P. Morgan Healthcare conference, as well as the subject matter of Juno’s presentations at the conference, including the plans, strategies, and objectives of management for future operations, including Juno’s manufacturing and process development, potential markets or market size for Juno’s product candidates, technology developments, its product pipeline, clinical data, competitive strengths and its position within the industry. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and increased regulatory requirements; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno’s business in general, see Juno’s Prospectus filed with the Securities and Exchange Commission on December 19, 2014. These forward-looking statements speak only as of the date hereof. Juno Therapeutics disclaims any obligation to update these forward-looking statements.